Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BacTR for bedaquiline-resistant rifampicin-resistant tuberculosis
PACTR202605753322997Phase 2Not yet recruiting
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amikacin and bedaquiline in Tuberculosis (TB), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: End-of-treatment success proportion. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
amikacinbedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202605753322997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605753322997.